| abstract |
Compounds useful as inhibitors of PDE4 in the treatment of diseases regulate d by the activation and degranulation of eosinophils, especially asthma, chron ic bronchitis, and chronic obstructive pulmonary disease, of the formula (I) wherein j is 0 or 1, provided that when j is 0, n must be 2; k is 0 or 1; m is 1, 2, or 3; n is 1 or 2; W1 and W2 are -O-; -S(=O)t-, where t is 0, 1, or 2, or -N(R3)-; Y is =C(R1a)-, or -[N.rArr.(O)k]- where k is 0 or 1; R1a is -H, - F, -Cl, -CN, -NO2, -(C1-C4) alkyl, -(C2-C4) alkynyl, fluorinated-(C1-C3) alkyl, fluorinated-(C1-C3) alkoxy, -OR16, or -C(=O)NR22aR22b; RA and RB are - H, -F, -CF3, -(C1-C4) alkyl, -(C3-C7) cycloalkyl, phenyl, or benzyl substituted by 0-3 R10; or RA and RB are taken together to form a spiro moie ty of the formula (Ia) where r and s are 0-4 provided r + s is >=1 but not & gt; 5; and XA is -CH2-, -CHF, -CF2, -NR15-, -O-, or -S(=O)t-, where t is 0, 1; RC a nd RD are the same as RA and RB except that one of them must be -H; R1 and R2 a re -H, -F, -Cl, -CN, -NO2, -(C1-C4) alkyl, -(C2-C4) alkynyl, fluorinated-(C1-C3 ) alkyl, -OR16, or -C(=O)NR22aR22b; R3 is -H, -(C1-C3) alkyl, phenyl, benzyl, or -OR16; R4, R5 and R6, D, J1 and J2 are defined in the application. |